ArticleFrontiers in immunology2021
Rapid Identification of the Tumor-Specific Reactive TIL Repertoire
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 26 citations in OpenAlex.
- Tumor Infiltrating Lymphocyte Therapy Combined With PD-1/LAG-3 Inhibition in Patients With Recurrent Platinum-Resistant Ovarian Cancer.International journal of cancer · 2026Article
- The proteomics and phosphoproteomics landscape of melanoma under T cell attack.Cell reports. Medicine · 2026Article
- Tumour-infiltrating lymphocyte therapy in melanoma: ready for prime time?British journal of cancer · 2026Review
- Review
- From Immunobiology to Clinical Application: Tumor-Infiltrating Lymphocytes in Melanoma.Journal of personalized medicine · 2026Review
- Immune Cell Modulation of Patient-Matched Organoid Drug Response in Precision Cancer Medicine Platform.Cells · 2026Article
- Tumour-infiltrating lymphocyte therapy landscape: prospects and challenges.BMJ oncology · 2025Review
- Adoptive cell therapy against tumor immune evasion: mechanisms, innovations, and future directions.Frontiers in oncology · 2025Review
- Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways.Cancer immunology research · 2024Article
- Developing innovative strategies of tumor‑infiltrating lymphocyte therapy for tumor treatment.Oncology reports · 2024Review
- Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma.Journal for immunotherapy of cancer · 2024Article
- Article
- Clinical-scale, modular manufacturing of tumor-reactive TILs using a closed and automated culture system.Frontiers in immunology · 2024Article
- CD4 Phenotypes Are Associated with Reduced Expansion of Tumor-Infiltrating Lymphocytes in Melanoma Patients Treated with Adoptive Cell Therapy.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- A novel transcriptional signature identifies T-cell infiltration in high-risk paediatric cancer.Genome medicine · 2023Article
- What do cancer-specific T cells 'see'?Discovery immunology · 2023Review
- LIGHT (TNFSF14) Costimulation Enhances Myeloid Cell Activation and Antitumor Immunity in the Setting of PD-1/PD-L1 and TIGIT Checkpoint Blockade.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- Review
- Potential biomarkers: Identifying powerful tumor specific T cells in adoptive cellular therapy.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Detecting the entire repertoire of tumor-specific reactive tumor-infiltrating lymphocytes (TILs) is essential for investigating their immunological functions in the tumor microenvironment. Current
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.